AJANTPHARM - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.1
| Stock Code | AJANTPHARM | Market Cap | 38,936 Cr. | Current Price | 3,115 ₹ | High / Low | 3,315 ₹ |
| Stock P/E | 41.1 | Book Value | 338 ₹ | Dividend Yield | 0.90 % | ROCE | 31.2 % |
| ROE | 24.1 % | Face Value | 2.00 ₹ | DMA 50 | 2,963 ₹ | DMA 200 | 2,791 ₹ |
| Chg in FII Hold | 0.29 % | Chg in DII Hold | -0.22 % | PAT Qtr | 197 Cr. | PAT Prev Qtr | 245 Cr. |
| RSI | 56.2 | MACD | 87.0 | Volume | 41,895 | Avg Vol 1Wk | 92,962 |
| Low price | 2,330 ₹ | High price | 3,315 ₹ | PEG Ratio | 2.04 | Debt to equity | 0.01 |
| 52w Index | 79.8 % | Qtr Profit Var | 1.99 % | EPS | 75.8 ₹ | Industry PE | 30.5 |
📊 Financial Overview:
AJANTPHARM demonstrates strong fundamentals with quarterly PAT at ₹197 Cr., though slightly lower than the previous ₹245 Cr. ROCE at 31.2% and ROE at 24.1% highlight excellent capital efficiency. Debt-to-equity is minimal at 0.01, ensuring financial stability. EPS stands at ₹75.8, supported by consistent profitability. Cash flows appear healthy given strong margins and low leverage.
💹 Valuation Indicators:
The stock trades at a P/E of 41.1, above the industry average of 30.5, indicating premium valuation. P/B ratio is ~9.2 (3115 ÷ 338), which is elevated. PEG ratio of 2.04 suggests moderate overvaluation relative to growth prospects. Dividend yield of 0.90% provides some investor returns. Intrinsic value appears slightly lower than current price, but strong fundamentals justify partial premium.
🏢 Business Model & Advantage:
AJANTPHARM operates in pharmaceuticals, benefiting from India’s healthcare demand and global generics market. Its competitive advantage lies in strong R&D, diversified product portfolio, and efficient capital use. Institutional sentiment is mixed, with FIIs increasing holdings (+0.29%) while DIIs reduced (-0.22%).
📈 Entry Zone:
Technically, support lies near ₹2,963 (50 DMA) and ₹2,791 (200 DMA). A favorable entry zone would be between ₹2,900–₹3,000 if the stock consolidates. Long-term investors may hold given strong fundamentals, though valuation suggests cautious accumulation.
Positive
- 📌 Strong ROCE (31.2%) and ROE (24.1%) indicate excellent efficiency.
- 📌 Very low debt-to-equity (0.01) ensures financial stability.
- 📌 EPS of ₹75.8 reflects robust profitability.
- 📌 FII holdings increased (+0.29%), showing foreign investor confidence.
Limitation
- ⚠️ P/E (41.1) is higher than industry average (30.5).
- ⚠️ P/B ratio (~9.2) is elevated.
- ⚠️ Quarterly PAT declined from ₹245 Cr. to ₹197 Cr.
- ⚠️ DII holdings decreased (-0.22%).
Company Negative News
- 📰 No major negative news reported, though recent profit decline raises caution.
Company Positive News
- 📰 Strong return ratios and minimal debt highlight financial health.
- 📰 FII inflows reflect confidence in long-term prospects.
Industry
- 🌐 Pharmaceutical industry is expanding with rising healthcare demand.
- 🌐 Industry P/E at 30.5 reflects growth potential, though AJANTPHARM trades at a premium.
Conclusion
✅ AJANTPHARM is financially strong with excellent return ratios, low debt, and robust profitability. Current valuations are slightly stretched, but fundamentals justify long-term holding. Entry is advisable near support levels (₹2,900–₹3,000). Investors should monitor quarterly earnings and institutional flows for sustained confidence.
For deeper insights, you could explore a peer comparison or a pharma sector outlook to complement this analysis.